For life sciences, it’s not only about when to bring on a GC...
For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.
Newsletters and Deep Dive digital magazine
For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.
Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.
Healthcare in the UK is at an inflection point.
AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
A bid to limit access to the abortion pill mifepristone in the US, while the FDA carries out a review of the drug, has been blocked in the courts.
Editor's Picks
Newsletters and Deep Dive
digital magazine